FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 23, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company...

VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model

VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model

SHANGHAI and BOSTON, April 18, 2025 /PRNewswire/ -- VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo), a biotech company with a robust discovery and development platform of multi-specific antibodies and antibody-drug conjugate...

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 antibody-drug conjugate EGFR and HER3 co-expressed across various solid tumors, including...

menu
menu